Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

David M. O’Malley, Ursula A. Matulonis, Michael J. Birrer, Cesar M. Castro, Lucy Gilbert, Ignace Vergote, Lainie P. Martin, Gina Mantia-Smaldone, Antonio González-Martı́n, Raquel Bratos, Richard T. Penson, Karim Malek, Kathleen N. Moore